Literature DB >> 28270496

Jab1/Csn5-Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress.

Fuling Zhou1,2,3, Yunbao Pan4,5, Yongchang Wei6, Ronghua Zhang2, Gaigai Bai3, Qiuju Shen3, Shan Meng3, Xiao-Feng Le7, Michael Andreeff8, Francois X Claret4,9.   

Abstract

Purpose: High levels of ROS and ineffective antioxidant systems contribute to oxidative stress, which affects the function of hematopoietic cells in acute myeloid leukemia (AML); however, the mechanisms by which ROS lead to malignant transformation in relapsed AML-M5 are not completely understood. We hypothesized that alterations in intracellular ROS would trigger AML-M5 relapse by activating the intrinsic pathway.Experimental Design: We studied ROS levels and conducted c-Jun activation domain-binding protein-1 (JAB1/COPS5) and thioredoxin (TRX) gene expression analyses with blood samples obtained from 60 matched AML-M5 patients at diagnosis and relapse and conducted mechanism studies of Jab1's regulation of Trx in leukemia cell lines.
Results: Our data showed that increased production of ROS and a low capacity of antioxidant enzymes were characteristics of AML-M5, both at diagnosis and at relapse. Consistently, increased gene expression levels of TRX and JAB1/COPS5 were associated with low overall survival rates in patients with AML-M5. In addition, stimulating AML-M5 cells with low concentrations of hydrogen peroxide led to increased Jab1 and Trx expression. Consistently, transfection of ectopic Jab1 into leukemia cells increased Trx expression, whereas silencing of Jab1 in leukemia cells reduced Trx expression. Mechanistically, Jab1 interacted with Trx and stabilized Trx protein. Moreover, Jab1 transcriptionally regulated Trx. Furthermore, depletion of Jab1 inhibited leukemia cell growth both in vitro and in vivoConclusions: We identified a novel Jab1-Trx axis that is a key cellular process in the pathobiologic characteristics of AML-M5. Targeting the ROS/Jab1/Trx pathway could be beneficial in the treatment of AML-M5. Clin Cancer Res; 23(15); 4450-61. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28270496      PMCID: PMC5861712          DOI: 10.1158/1078-0432.CCR-16-2426

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  38 in total

Review 1.  Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel?

Authors:  Simran S Sabharwal; Paul T Schumacker
Journal:  Nat Rev Cancer       Date:  2014-11       Impact factor: 60.716

2.  Chemistry and biology of reactive oxygen species in signaling or stress responses.

Authors:  Bryan C Dickinson; Christopher J Chang
Journal:  Nat Chem Biol       Date:  2011-07-18       Impact factor: 15.040

Review 3.  Mitochondrial ROS regulation of proliferating cells.

Authors:  Lauren Diebold; Navdeep S Chandel
Journal:  Free Radic Biol Med       Date:  2016-05-03       Impact factor: 7.376

Review 4.  Role of nrf2 in oxidative stress and toxicity.

Authors:  Qiang Ma
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013       Impact factor: 13.820

5.  Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation.

Authors:  Sameh Gaballa; Rima Saliba; Betul Oran; Jonathan E Brammer; Julianne Chen; Gabriela Rondon; Amin M Alousi; Partow Kebriaei; David Marin; Uday R Popat; Borje S Andersson; Elizabeth J Shpall; Elias Jabbour; Naval Daver; Michael Andreeff; Farhad Ravandi; Jorge Cortes; Keyur Patel; Richard E Champlin; Stefan O Ciurea
Journal:  Am J Hematol       Date:  2017-02-13       Impact factor: 10.047

6.  Thioredoxin modulates activator protein 1 (AP-1) activity and p27Kip1 degradation through direct interaction with Jab1.

Authors:  Chae Young Hwang; Yeung Sook Ryu; Mi-Sun Chung; Kwang Dong Kim; Sung Sup Park; Suhn-Kee Chae; Ho Zoon Chae; Ki-Sun Kwon
Journal:  Oncogene       Date:  2004-11-25       Impact factor: 9.867

7.  Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling.

Authors:  Paul S Hole; Joanna Zabkiewicz; Chinmay Munje; Zarabeth Newton; Lorna Pearn; Paul White; Nuria Marquez; Robert K Hills; Alan K Burnett; Alex Tonks; Richard L Darley
Journal:  Blood       Date:  2013-10-02       Impact factor: 22.113

Review 8.  ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis.

Authors:  Benoît D'Autréaux; Michel B Toledano
Journal:  Nat Rev Mol Cell Biol       Date:  2007-10       Impact factor: 94.444

9.  Mitochondrial oxidative stress drives tumor progression and metastasis: should we use antioxidants as a key component of cancer treatment and prevention?

Authors:  Federica Sotgia; Ubaldo E Martinez-Outschoorn; Michael P Lisanti
Journal:  BMC Med       Date:  2011-05-23       Impact factor: 8.775

10.  EM23, A Natural Sesquiterpene Lactone from Elephantopus mollis, Induces Apoptosis in Human Myeloid Leukemia Cells through Thioredoxin- and Reactive Oxygen Species-Mediated Signaling Pathways.

Authors:  Hongyu Li; Manmei Li; Guocai Wang; Fangyuan Shao; Wenbo Chen; Chao Xia; Sheng Wang; Yaolan Li; Guangxiong Zhou; Zhong Liu
Journal:  Front Pharmacol       Date:  2016-03-29       Impact factor: 5.810

View more
  22 in total

1.  CSN5 Promotes Hepatocellular Carcinoma Progression by SCARA5 Inhibition Through Suppressing β-Catenin Ubiquitination.

Authors:  Hongliang Liu; Junwen Hu; Hua Pan; Dilai Luo; Mingwen Huang; Wei Xu
Journal:  Dig Dis Sci       Date:  2017-11-30       Impact factor: 3.199

2.  1,3-Benzodioxole Derivatives Improve the Anti-Tumor Efficiency of Arsenicals.

Authors:  Xue-Min Shi; Wen-Yan She; Ting-Ting Liu; Lian-Xun Gao; Yu-Jiao Liu; Yi Liu
Journal:  Int J Mol Sci       Date:  2022-06-22       Impact factor: 6.208

3.  COP9 signalosome complex subunit 5, an IFT20 binding partner, is essential to maintain male germ cell survival and acrosome biogenesis†.

Authors:  Qian Huang; Hong Liu; Jing Zeng; Wei Li; Shiyang Zhang; Ling Zhang; Shizhen Song; Ting Zhou; Miriam Sutovsky; Peter Sutovsky; Ruggero Pardi; Rex A Hess; Zhibing Zhang
Journal:  Biol Reprod       Date:  2020-02-12       Impact factor: 4.285

4.  JAB1 promotes palmitate-induced insulin resistance via ERK pathway in hepatocytes.

Authors:  Yun Zhao; Suxian Ma; Xingna Hu; Min Feng; Rong Xiang; Min Li; Chenxiao Liu; Ting Lu; Aijie Huang; Jiaqi Chen; Mian Wu; Honghong Lu
Journal:  J Physiol Biochem       Date:  2020-10-14       Impact factor: 4.158

Review 5.  Jab1/Cops5: a promising target for cancer diagnosis and therapy.

Authors:  Chunjue Yuan; Dong Wang; Guohong Liu; Yunbao Pan
Journal:  Int J Clin Oncol       Date:  2021-05-21       Impact factor: 3.402

6.  Increased Jab1/COPS5 is associated with therapeutic response and adverse outcome in lung cancer and breast cancer patients.

Authors:  Junna Hou; Guohong Liu; Yufen Yuan; Dong Wang; Pengfei Jiao; Lihua Xing; Yunbao Pan
Journal:  Oncotarget       Date:  2017-10-27

7.  Azelaic Acid Exerts Antileukemic Activity in Acute Myeloid Leukemia.

Authors:  Yunbao Pan; Dong Liu; Yongchang Wei; Dan Su; Chenyang Lu; Yanchao Hu; Fuling Zhou
Journal:  Front Pharmacol       Date:  2017-06-12       Impact factor: 5.810

Review 8.  Jab1/COPS5 as a Novel Biomarker for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Human Cancer.

Authors:  Guohong Liu; Francois X Claret; Fuling Zhou; Yunbao Pan
Journal:  Front Pharmacol       Date:  2018-02-27       Impact factor: 5.810

Review 9.  Reactive oxygen species in haematopoiesis: leukaemic cells take a walk on the wild side.

Authors:  Rodrigo Prieto-Bermejo; Marta Romo-González; Alejandro Pérez-Fernández; Carla Ijurko; Ángel Hernández-Hernández
Journal:  J Exp Clin Cancer Res       Date:  2018-06-26

10.  Compound kushen injection suppresses human acute myeloid leukaemia by regulating the Prdxs/ROS/Trx1 signalling pathway.

Authors:  Yanxia Jin; Qian Yang; Li Liang; Lu Ding; Yuxing Liang; Dongdong Zhang; Balu Wu; Tian Yang; Hailing Liu; Tingting Huang; Hui Shen; Honglei Tu; Yunbao Pan; Yongchang Wei; Yi Yang; Fuling Zhou
Journal:  J Exp Clin Cancer Res       Date:  2018-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.